BAX and breast carcinoma: Conversely, Sharifi et al. reported the favorable outcome in high BCL2/BAX ratio in Paclitaxel resistant breast cancer cell-line (25), and Jaafar et al. reported no significance between BCL2, BAX expression and breast tumor cells and angiogenesis of the tumor (26).